Global Retinitis Pigmentosa Market, By Type (Autosomal Recessive, Autosomal Dominant, X-Linked), Treatment (Vitamin A, Docosahexaenoic acid (DHA), Calcium channel blockers, Gene therapy, Retinal eye prosthetics, Others), Route of Administration (Oral, Topical, Others), Diagnosis (Electroretinogram, Visual Field Testing, Genetic Testing, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In recent years, the retinitis pigmentosa market is anticipated to grow rapidly during the forecast period. According to researchers, a total of 30,000 to 50,000 people are suffering from retinitis pigmentosa. Because there is no cure for retinitis pigmentosa, most persons who are affected by the hereditary ailment move to the severe stage of the disease. It has, however, created an opening for new medicines and treatments. Manufacturers from the ophthalmology sector are currently investigating a novel strategy known as optogenetics, which includes gene therapy to restore vision. It aids the ability of cells, particularly ganglion cells, to respond to light following the degeneration of rod and cone cells.
Data Bridge Market Research analyses that the retinitis pigmentosa market was valued at USD 11.57 billion in 2021 and is expected to reach USD 20.33 billion by 2029, registering a CAGR of 7.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Retinitis pigmentosa (RP) is a series of rare hereditary illnesses characterized by cell death and breakdown in the retina, the light-sensitive tissue that lines the back of the eye. Both common complaints are night vision problems and a loss of side (peripheral) vision. Retinitis pigmentosa is caused by mutations in one or more of the more than 50 genes. Photoreceptors are proteins produced by these genes. These genes cannot make the protein due to a mutation or alteration, leading to retinitis pigmentosa.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Autosomal Recessive, Autosomal Dominant, X-Linked), Treatment (Vitamin A, Docosahexaenoic acid (DHA), Calcium channel blockers, Gene therapy, Retinal eye prosthetics, Others), Route of Administration (Oral, Topical, Others), Diagnosis (Electroretinogram, Visual Field Testing, Genetic Testing, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Bausch Health Companies Inc. (Canada), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Allergan (Ireland), Astellas Pharma Inc. (Japan), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Orphagen Pharmaceuticals, Inc (US), Clino Corporation (Japan), Spark Therapeutics, Inc (US), Caladrius Biosciences, Inc. (US), Genethon (France), Gensight Biologics(France), Grupo Ferrer International, S.A. (Spain), Nanovector S.r.l (Italy), Mimetogen Pharmaceuticals Inc. (Canada), Ionis Pharmaceuticals, Inc. (US), AGTC (US), MeiraGTx Limited (US), ReNeuron Group plc (UK), ProQR Therapeutics. (Netherlands)
|
|
Market Opportunities
|
|
Retinitis Pigmentosa Market Dynamics
Drivers
- Increasing prevalence of retinitis pigmentosa
The rising prevalence of retinitis pigmentosa is anticipated to influence the market's growth during the forecast period. The growing number of inherited disorders and gene mutations in the eye are the various factors developing the risk of retinitis pigmentosa.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of retinitis pigmentosa market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the retinitis pigmentosa market. Additionally, high disposable income and surging demand for disease novel treatment will result in the expansion of retinitis pigmentosa market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the retinitis pigmentosa market growth. Along with this, rising approvals and launches of new retinitis pigmentosa drugs will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the retinitis pigmentosa market growth during the forecast period.
Restraints/Challenges
On the other hand, limited treatment options for retinitis pigmentosa will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the retinitis pigmentosa market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of cure for retinitis pigmentosa among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This retinitis pigmentosa market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the retinitis pigmentosa market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Retinitis pigmentosa is an uncommon illness passed down from one generation to the next. It hardly affects 1 in every 4,000 people. A family member with retinitis pigmentosa affects almost half of all persons with the disease.
Retinitis pigmentosa market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Retinitis Pigmentosa Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of retinitis pigmentosa in recent months.
Recent Development
- In January 2022, 4D Molecular Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted the fast track designation to 4D-125 which is used to treat X-linked retinitis pigmentosa. 4D-125 is a targeted and evolved R100-based product candidate meant to deliver a functional copy of the RPGR gene to photoreceptors in the retina. It was invented at 4DMT for efficient intravitreal delivery.
Global Retinitis Pigmentosa Market Scope
The retinitis pigmentosa market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Autosomal Recessive
- Autosomal Dominant
- X-Linked
Treatment
- Vitamin A
- Docosahexaenoic acid (DHA)
- Calcium channel blockers
- Gene therapy
- Retinal eye prosthetics
- Others
Route of Administration
- Oral
- Topical
- Others
Diagnosis
- Electroretinogram
- Visual Field Testing
- Genetic Testing
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Retinitis Pigmentosa Market Regional Analysis/Insights
The retinitis pigmentosa market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the retinitis pigmentosa market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the retinitis pigmentosa market because of the growing number of research and development activities and the presence of refined healthcare expenditure in this region. Additionally, presence of major key players is projected to propel the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to the increasing presence of generic manufacturers and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Retinitis Pigmentosa Market Share Analysis
The retinitis pigmentosa market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to retinitis pigmentosa market.
Some of the major players operating in the retinitis pigmentosa market are:
- Bausch Health Companies Inc. (Canada)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Allergan (Ireland)
- Astellas Pharma Inc. (Japan)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Orphagen Pharmaceuticals, Inc (US)
- Clino Corporation (Japan)
- Spark Therapeutics, Inc (US)
- Caladrius Biosciences, Inc. (US)
- Genethon (France)
- Gensight Biologics(France)
- Grupo Ferrer International, S.A. (Spain)
- Nanovector S.r.l (Italy)
- Mimetogen Pharmaceuticals Inc. (Canada)
- Ionis Pharmaceuticals, Inc. (US)
- AGTC (US)
- MeiraGTx Limited (US)
- ReNeuron Group plc (UK)
- ProQR Therapeutics. (Netherlands)
SKU-